← Nuvation Bio Inc. (NUVB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Nuvation Bio Inc. (NUVB)
Pharmaceutical Preparations · market cap $2.1B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
5
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Nuvation Bio (NUVB) is a clinical-stage pharmaceutical company with a market cap of ~$2.05B and a diversified oncology pipeline anchored by taletrectinib (Phase 3, NSCLC) and safusidenib (Phase 3, Glioma). The company faces two near-term PDUFA dates — NUV-868 in October 2026 and taletrectinib in January 2027 — making the next six months a binary-heavy period. Cash stands at $125.4M against a net cash position of $72.3M, and dilution risk is flagged as elevated at 23%.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
- 2027-01-04PDUFA · Taletrectinibimp 8/10
- 2027-01-04 (est.)NDA Filingimp 7/10
- 2027-03-15 (est.)Phase 2 · NUV-1511imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Taletrectinib | Phase 3 | Non Small Cell Lung Cancer |
| NUV-1511 | Phase 2 | Advanced Solid Tumor |
| Crizotinib | Phase 3 | Non Small Cell Lung Cancer |
| safusidenib | Phase 3 | Glioma |
| AB-106 | Phase 2 | Non Small Cell Lung Cancer |
Price & technical context
3-month
+3.3%
6-month
+30.5%
12-month
+73.9%
52-wk range
$3.41–$9.54
vs 50-day MA
-12.4%
vs 200-day MA
-3.6%
Realized vol
80.5%
Max drawdown
-57.5%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NUVB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.